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Abstract
Alzheimer’s disease (AD) is a devastating illness characterized by a progressive loss of
cognitive, social, and emotional functions, including memory impairments and more global
cognitive deficits. Clinical-epidemiological evidence suggests that neuropsychiatric symp-
toms precede the onset of cognitive symptoms both in humans with early and late onset
AD. The behavioural profile promoted by the AD pathology is believed to associate with
degeneration of the serotonergic system. Using the APPswe/PS1δE9 model of AD-like
pathology starting with 9 months old mice, we characterised long term non-cognitive beha-
vioural changes measured at 9, 12, 15, and 18 months of age and applied principal compo-
nent analysis on data obtained from open field, elevated plus maze, and social interaction
tests. Long-term treatment with the selective serotonin reuptake inhibitor (SSRI) paroxetine
was applied to assess the role of 5-HT on the behavioural profile; duration of treatment was
9 months, initiated when mice were 9 months of age. Treatment with paroxetine delays the
decline in locomotion, in exploration and risk assessment behaviour, found in the APP/PS1
mice. APP/PS1 mice also exhibit low social activity and less aggressiveness, both of which
are not affected by treatment with paroxetine. The APP/PS1 behavioural phenotype, dem-
onstrated in this study, only begins to manifest itself from 12 months of age. Our results
indicate that treatment with SSRI might ameliorate some of the behavioural deficits found in
aged APP/PS1 mice.
Introduction
Alzheimer’s disease (AD) is a devastating illness characterized by a progressive loss of cogni-
tive, social and emotional functions, usually starting with memory impairment followed by
more global cognitive deficits and neuropsychiatric symptoms, such as agitation, aggression,
anxiety and depressive symptoms [1]. In terms of the neuropathology, one of the hallmarks of
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AD is the deposition of amyloid-ß (Aß) peptides in extracellular plaques, which starts years
before the clinical symptoms [2]. Clinical-epidemiologicalevidence suggests that neuropsychi-
atric symptoms precede the onset of cognitive symptoms in both early and late onset AD [3, 4].
A dysfunction in the serotoninergic (5-HT) system has been implicated in both AD pathology
[5, 6] and in the associated neuropsychiatric symptoms [7].
The Aß plaque burden has been shown to correlate to 5-HT4 receptor levels in AD [8], and
post mortem studies have demonstrated reduced density of 5-HT neurons in the raphe nuclei
in AD patients [5, 9]. This decrease in 5-HT neuron number correlates to reduced levels of
5-HT in various brain areas in patients suffering from AD (reviewed in [10, 11]), and the
changes in the serotoninergic transmitter systemmight contribute to the occurrence of the
neuropsychiatric symptoms observed in AD [7].
In the APPswePS1δE9 transgenic mouse model of AD a progressive loss of forebrain seroto-
ninergic axons has been demonstrated, from 12 months of age, to correlate with reduced levels
of 5-HT [12]. In the same study a significant loss of serotoninergic neurons in the raphe nuclei
in 18 months old mice was found to correlate with Aß deposits [12], which starts to develop
from 3–4 months of age in this mouse model [13]. In the APPswe/PS1δE9 (APP/PS1) model Liu
et al. [12] reports 5-HT neurodegeneration to precede the onset of anxiety-related behaviours,
such as thigmotaxis, becoming evident from 18 months of age, and also to precede reduced
motor activity in the open field (OF) test, apparent from 24 months of age. Most behavioural
studies on APP/PS1 mice have been performed at a much earlier age, where 5-HT related dys-
function is not yet evident. Thus, to assess the possible effect of 5-HT related dysfunction on
behaviour in the APP/PS1 model of AD, there is a need to assess behavioural changes well
beyond 12 months of age, when loss of serotoninergic axons is initially observed.
Treatment with selective serotonin reuptake inhibitors (SSRIs) has been found to improve
several cognitive and neuropsychiatric symptoms associated with AD [14]. Interestingly, the
effect of antidepressant drugs has also been associated with lower Aß levels and plaque burden
in both cortical and hippocampal regions in the APP/PS1 mice as well as in cortical regions of
human subjects [15]. In fact, chronic treatment with citalopram, beginning at 3 months of age,
before the onset of insoluble Aß deposits, was shown to impede the development of Aß deposi-
tion in 7-month-old APP/PS1 mice [15]. A recent study on 12-month old APP/PS1 mice, with
established Aß pathology, indicated acute citalopram treatment to reduce Aß levels in brain
interstitial fluid (ISF) in a dose-dependentmanner, and chronic treatment to arrest individual
plaque growth and to reduce new plaque formation in cortex [16]. Citalopram has also been
found to reduce Aß levels in the CSF of healthy human subjects in one study [16], however,
this finding was not replicated in a different study [17]. Long-term treatment with another
SSRI, paroxetine, was found to delay development of Aß pathology and ameliorate behavioural
deficits in another AD transgenic mouse model (3xTgAD) [18], which also exhibits dysfunc-
tions in the 5-HT neurotransmitter system [19].
Here, we assessed the implications of a dysfunctional 5-HT system on mouse behaviour
during aging using the APP/PS1 model of AD, starting at 9 months of age, when Aß pathology
is well established [13, 20] and 5-HT axonal degeneration is not yet evident [21]. Hence, any
abnormal behaviour at this time point will most likely not be attributed 5-HT signalling. Long-
term treatment with paroxetine initiated at 9 months of age will further allow for evaluation of
the correlation between development of AD-like pathology, 5-HT dysfunction, and behaviour.
To our knowledge, the present study is the first longitudinal study investigating the effect of
paroxetine on behavioural changes in the APP/PS1 mouse model.We describe the develop-
ment of a behavioural phenotype from 9 to 18 months of age, which might be 5-HT-related.
Furthermore, we analyse the effect of pharmacological intervention that is known to increase
extracellular 5-HT levels in the brain [22]. We use principal component analysis to assess
Phenotyping of an Alzheimer’s Disease Mouse Model following Paroxetine Treatment
PLOS ONE | DOI:10.1371/journal.pone.0165144 November 4, 2016 2 / 21
Competing Interests: The authors have declared
that no competing interests exist.
behavioural patterns that can be drawn from an extensive set of behavioural variables.We
believe that this study will add to the overall behavioural characterisation of the APP/PS1
mouse model, as well as shed light upon the correlation between 5-HT dysfunction and abnor-
mal behaviour.
Materials and Methods
Animals
Ethics statement. Mice were submitted to daily inspections and observations, however, no
harmful effects of either genotype or treatment were observed and consequently no mice were
euthanized before termination of the study. It is well-known, however, that hemizygous
APPswe/PS1δE9 Tg mice show an increasedmortality, without showing signs of previous dis-
ease, compared to littermate wildtype (WT) mice. Video−EEGmonitoring shows that hemizy-
gous Tg mice more frequently than wildtypemice, show seizure activity, which might be the
reason behind the increasedmortality. We observed an increased sudden (unexpected)mortal-
ity of Tg, but not WTmice treated with the initial high dose of paroxetine (30 mg/kg/day),
while the survival of the Tg mice treated with the lower doses of paroxetine was unaffected. All
casualties were reported to the ethics committee. Mainly coat state and body weight were used
as readouts on a healthy state. At study terminationmice were euthanized by a lethal dose of
pentobarbital. Health status was monitored by daily inspections of coat state and general well
being. Bodyweightwas measured regularly. There was no apparent suffering of animals.
Double transgenic (Tg) APPSWE/PSδE9 (APP/PS1) mice, and littermate wild type (Wt) mice
were bred on a B6C3 hybrid background (C57BL/6 X C3H/HeN) in the Biomedical Laboratory,
University of SouthernDenmark (n = 51) or at Taconic A/S, Denmark (n = 55). Mice were geno-
typed in-house, and animals carrying the rd/rd mutation [23, 24] were excluded. A total of 106
male mice were used in this study. Because of high levels of aggressive behaviour in this mouse
model, animals were singly housed from 9 months of age. Animals were kept under standard lab-
oratory conditions, i.e. food and water ad libitum, 12-h light/dark cycle (lights on at 6:00 p.m.)
with constant temperature (21 ± 2°C) and humidity (52 ± 2%). Bodyweight and fluid intake was
monitored regularly throughout the study. Animals were exposed to environmental enrichment
consisting of wood splints bedding, chewing stick, access to beddingmaterial, and mouse house.
Cages were from Tecniplast, type III (425 x 266 x 155 mm). The Danish National Committee for
Ethics in Animal Experimentation approved all animal procedures (2013-15-2934-00814).
Paroxetine treatment
Paroxetine (Seroxat1 oral solution 2 mg/ml, GSKline) was administered in drinkingwater ini-
tially at a dose of 30 mg/kg/day, which based on measurements of serum paroxetine was
adjusted to 10 mg/kg/day and finally 5 mg/kg/day, corresponding to reported intraperitoneal
dosing of 3xTgADmice [18]. Treatment was initiated at 9 months of age, and was continued
for a duration of 9 months. Tap water was used as vehicle. Serumparoxetine concentrations
were monitored by UHPLC-MS/MS prior to, and subsequent to 3 months of treatment. Blood
samples were collected and centrifuged for 10 min at 7000 rpm, the supernatant was stored at
-80°C until further analysis.
The analysis of paroxetine was based on a previous method with fewmodifications [25].
Fifteen μl of serumwas diluted with 45 μl water. Paroxetine-d4 was used as internal standard
in a concentration of 300 nmol/l, and the mass spectrometer Agilent triple quadrupole 6460
(G6460B) was used for quantification. Two MRM transitions were monitored for both paroxe-
tine and the internal standard (paroxetine: 330–192 and 330–70; paroxetine-d4: 334–196 and
334–74). Calibration was performed by linear calibration based on five-points. The
Phenotyping of an Alzheimer’s Disease Mouse Model following Paroxetine Treatment
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measurement range was 50–20,000 nmol/l corresponding to the lower and upper limit of quan-
tification. Effects of ion suppression were minimal. Precision was less than 15% coefficient of
variation and trueness was within the range of 85–115%.
Behavioural testing
Mice were subjected to a set of behavioural tests in order to assess the effect of age, genotype and
treatment on various behavioural parameters. The Open Field (OF) and the Elevated Plus Maze
(EPM) tests were used for evaluating anxiety-like behaviour, explorative behaviour and general
locomotion. The Social Interaction (SI) test was used to evaluate social behaviour, including
aggressive behaviour and memory for social interaction. Testing was done at 9, 12, 15 and 18
months of age, corresponding to 0, 3, 6 and 9 months of treatment, respectively. The animals
were tested during the first half of the light phase in the light/dark cycle. Behavioural parameters
were registered and scored by one or two experienced investigators. All test apparatuses were
cleaned between individual test sessions with 70% ethanol and rinsedwith water/wet paper towel.
Behavioural variables were abbreviated as indicated in Table 1. In the OF and EPM tests a
total of 24 behavioural variables were scored and in the SI test 10 behavioural variables were
registered.
After behavioural assessment at 9 months of age (treatment time = 0) animals were subse-
quently split into 4 experimental groups: Tg andWt with no treatment, and Tg andWt with
paroxetine treatment. All together the study comprised 4 experimental groups, which were
studied at 4 different time points. For each of the behavioural variables registered we made 198
observations in the OF and EPM tests and 221 observations in the SI test.
At 9 months of age, a total of 55 (30Wt; 25 Tg)mice were included in the analysis. At 12
months of age a total of 46 mice (12 TgVeh; 4 TgPrx; 15WtVeh; 15WtPrx) mice were included
in the analysis. At 15 months of age a total of 47 mice (12 TgVeh; 6 TgPrx; 15WtVeh; 15
WtPrx) were included in the OF/EPM analysis, and 68 mice (22 TgVeh; 9 TgPrx; 23WtVeh; 14
WtPrx) in the SI analysis. At 18 months of age a total of 50 mice (12 TgVeh; 8 TgPrx; 14
WtVeh; 16WtPrx) were included in the OF/EPM analysis, and 68 mice (12 TgVeh; 7 TgPrx; 19
WtVeh; 16WtPrx) in the SI analysis.
Open field test. The open field (OF) test was performed in a rectangular arena (60
cm × 80 cm, surrounded by 60 cm-high walls), made of dark painted wood. The arena was
divided into 48 squares (10x10 cm) for visual scoring of activity. The mice were individually
placed in one of the corners facing the perimeter, and allowed to explore the test arena freely
for the entire test session (3 min). The following parameters were recorded; total distance trav-
elled, rearing against the perimeter wall, free rearing, number of entries in the central area,
time spent on immobility, stereotypy, grooming, and number of faecal boli as well as amount
of urine traces and freezing incidents.
Elevatedplus maze test. The Elevated Plus Maze (EPM) consisted of two sets of opposing
arms, two open (30 cm × 5 cm) and two enclosed (30 cm × 5 cm, surrounded by 16 cm-high
walls), made of black Plexiglas and elevated 80 cm above the floor. The mice were individually
placed on the central platform, at the junction of the four arms, with head facing against an
open arm, and left freely to explore the test arena for the entire test session (5 min). Following
parameters were recorded: Latency to first entry into either of the arms, time of immobility, the
number of entries into open and closed arms, the time spent in open and closed arms, rearing
in open and closed arms, stretch-attend posture, head-dips, grooming and number of faecal
boli, amount of urine traces, and freezing incidents.
Social interaction test. The social interaction (SI) test was performed on two consecutive
days in a rectangular arena (60 cm × 80 cm, surrounded by 60 cm-high walls). The tests were
Phenotyping of an Alzheimer’s Disease Mouse Model following Paroxetine Treatment
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on both days initiated by simultaneously placing a test mouse and a Wt male intrudermouse
in opposite corners of the arena, facing the wall. The same test/intrudermice were paired on
both days. During a 3-min test session the following parameters were registered; latency to ini-
tial contact, time spent in contact, number of social actions performed by the test mouse, num-
ber of aggressive incidents and time spent on aggressive behaviour. The intrudermice were
age-matched male B6C3 (Wt) mice.
6E10 immunohistochemistry and Aß plaque load estimation
To estimate the Aß plaque load mice were deeply anaesthetized, and perfusedwith 10 ml phos-
phate buffered saline (PBS) followed by 20 ml of 4% paraformaldehyde (PFA). Brains were
additionally fixed in 4% PFA for 24 h followed by 1% PFA for 24 h. The left hemisphere was
Table 1. Abbreviation of behavioural variables scored during testing.
Test Behavioural parameter Abbreviation
Open Field Total squares crossed SqCOF
Rearing against walls RWOF
Rearing, freestanding ROF
Central crossing CCOF
Immobility time ITOF
Stereotypy StOF
Grooming GrOF
Faecal Boli BOF
Urine UOF
Freezing FrOF
Elevated Plus Latency LatEPM
Maze Immobility time ITEPM
Open arms, number of entries OANEPM
Open arms, time spent in OATEPM
Closed arms, number of entries CANEPM
Closed arms, time spent in CATEPM
Rearing, Closed arms RCEPM
Stretch-attend posture SAPEPM
Head dips, Open arms HDOEPM
Head dips, Closed arms HDCEPM
Grooming GrEPM
Faecal Boli BEPM
Urine UEPM
Freezing FrEPM
Social Interaction, Latency to first interaction LatS1
Day 1 Time spent in contact TS1
Contacts, number of CS1
Aggression, nb of incidents AgS1
Aggression, time spent on AgTS1
Day 2 Latency to first interaction LatS2
Time spent in contact TS2
Contacts, number of CSI2
Aggression, nb of incidents AgSI2
Aggression, time spent on AgTSI2
doi:10.1371/journal.pone.0165144.t001
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marked and the brains were sectioned in a vibratome (Leica, DK) into 50 μm thick free-floating
sections which were stored in de Olmos solution at -14°C.
Prior to staining sections were demasked in 70% formic acid diluted in H2O for 15 min at
room temperature (RT), followed by rinsing in tris buffered saline (TBS) and TBS + 1% Triton
(TBS/T), and pre-incubation in TBS/T + 10% fetal bovine serum (TBS/T/FBS). Then followed
incubation with the biotinylated monoclonal mouse-anti-Aß antibody (6E10, SIG-39340, Bio-
site) diluted 1:500, first 30 min at RT and next o.n. at 4°C, using biotinylated isotype IgG1
diluted 1:50 (MG115, Invitrogen) as control. Next day the sections were rinsed in TBS/T,
blocked in TBS/Methanol/H202 (8:1:1) for 10 min, and rinsed in TBS and TBS/T followed by
incubation with Horse Radish Peroxidase-Streptavidin diluted 1:200 (RPN1231V, GE Health-
care) in TBS/T/FBS for 1 h at RT. After rinsing in TBS sections were developedwith 3,3’-diami-
nobenzidine (DAB) for 10 min followed by rinsing in TBS. The sections were finally mounted
on gelatine-coated glass slides, dehydrated in ethanol, cleared in xylene and coverslipped in
Depex (Sigma).
The Aß plaque load was estimated in the right neocortex of two sections obtained from the
level of the anterior commisure in 5 mice/group. For the estimation was used a stereological
grid counting technique using the new CAST software (Visiopharm) as described in Babcock
et al. (2015). The neocortexwas delineated using a 4x magnification, and a grid stepping over
the neocortexwith a (x,y) step length of 286.5 μm x 216 μm and containing a similarly sized
frame, with systematically placed crosses was used. Only plaques touching the centre of a cross
were counted. The percentage of the neocortex covered by plaques was calculated as follows:
Aß plaque load (%) = No. of Aß+ plaques touching a cross / No. of crosses in neocortex x
100%. The Aß plaque load in individual mice was calculated as the average of the Aß plaque
load in the two sections. Data are presented as Mean ± SD.
Data analysis
For all statistical analyses XLSTAT (version 2010.3.06) was used. All data sets were tested for
normality of distribution by Shapiro-Wilk and Jarque-Bera tests. The Bartlett’s test was used to
check the uniformity of variances. The criterion for statistical significancewas set at p< 0.05.
All data fromOF, EPM and SI tests were subjected to principal component analysis (PCA). Aß
plaque load was analysed by Student’s t-test. The Pearson product-moment correlation coeffi-
cient (Pearson’s r) analysis was used as a measure of correlation betweenAß plaque load and
behavioural variables.
Principal component analysis
Principal component analysis (PCA) was applied in order to reduce the number of behavioural
variables shown in Table 1. We conducted PCA on results from OF and EPM, examining gen-
eral activity, exploratory activity and anxiety, and a separate PCA on data from SI, focusing on
social behaviour. In both cases the Spearman’s correlation matrix was used. Data were sub-
jected to Oblimin rotation with Kaiser normalization and Tau = 0, as recommended for beha-
vioural data, to avoid bias towards the first principal component [26].
From principal component analysis on OF and EPM variables, 7 factors were extractedwith
eigenvalues higher than 1 (accounting for 65% of total variability). Examination of the Scree-
plot indicated that a solution with 3 factors would be appropriate. As recommend by Abdi and
Williams [27] we tried several rotation analyses on data fromOF and EPM tests retaining dif-
ferent numbers of factors to assess robustness of the interpretation. Consequently, four princi-
pal components (PCs) were extracted, as they were considered of biological relevance.
Phenotyping of an Alzheimer’s Disease Mouse Model following Paroxetine Treatment
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The principal component analysis on results from the SI test extracted 4 factors with eigen-
value higher than 1 (accounting for 71% of total variability), which were retained for Oblimin
rotation. Factor definitions and factor loadings obtained after Oblimin rotation are shown in
Table 2 and Table 3, respectively.
Table 2. Description of factors and factor loadings obtained by PCA using Oblimin rotation on behavioural variables assessed by OF and EPM
test.
Factors Variables Factor Loadinga Contribution (%) of the variables
Factor D1: Locomotion and anxiety-like behaviour SqCOF 0.954 11.218
RWOF 0.922 10.474
ROF 0.940 10.895
CCOF 0.958 11.318
BOF -0.960 11.365
ITOF -0.749 6.925
StOF -0.923 10.506
LatEPM 0.744 6.826
BEPM -0.957 11.299
Factor D2: Anxiety OANEPM 0.975 23.435
OATEPM 0.983 23.818
CATEPM -0.831 17.011
HDOEPM 0.913 20.529
Factor D3: Exploration and risk assessment ITEPM -0.851 14.622
CANEPM 1.008 20.514
RCEPM 0.951 18.258
HDCEPM 1.015 20.802
SAPEPM 0.789 12.572
Factor D4: Stress-related vegetative behaviour GrOF 0.863 16.167
UOF -0.881 16.860
GrEPM 1.006 21.999
UEPM -0.920 18.374
aFactor loadings < 0.6 were not included in the table.
doi:10.1371/journal.pone.0165144.t002
Table 3. Description of factors and factor loadings obtained by PCA using Oblimin rotation on behavioural variables assessed by SI test.
Factors Variables Factor loadinga Contribution (%) of the variables.
Factor S1: AgS2 1.001 43.863
Fighting/Aggression AgTS2 0.991 42.996
Factor S2: LatS1 -1.021 33.731
Social activity TS1 0.948 29.044
CS1 0.691 15.430
LatS2 -0.811 21.286
Factor S3: AgS1 0.963 44.336
Aggression AgTS1 1.015 49.224
Factor S4: TS2 0.847 31.839
Memory for Social Interaction CS2 0.976 42.249
aFactor loadings < 0.6 were not included in the table.
doi:10.1371/journal.pone.0165144.t003
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Multivariate analysis of variance on principal components
The PCA scores were extracted and the resulting new variables (principal components) were
normally distributed. Effect of age, genotype and treatment was tested usingMultivariate Anal-
ysis of Variance followed by Fisher’s Least SignificanceDifference (LSD) post hoc test for pair-
wise analysis. The criterion for statistical significancewas set at p< 0.05. Factor scores are
presented as Mean ± SEM.
Results
According to the study design animals at 9 months of age (treatment time = 0) were split into 4
experimental groups, which were studied at 4 different time points. Twenty-four variables were
recorded in the OF and EPM tests, and 10 in the social interaction test. For each of the beha-
vioural variables registered we made 198 observations in the OF and EPM tests and 221 obser-
vations in the SI test. Statistics on the individual behavioural variables from each of the 3
behavioural tests is available in supporting information. In order to reduce the number of beha-
vioural variables from a total of 34 to 8, principal component analyses (PCA) were conducted.
All behavioural variables described in Table 1 were included in the PCA, except for freezing
behaviour, which was observedonly on 3 occasions.
Paroxetine levels
The serum paroxetine levels frommice at 9 and 12 months of age, corresponding to 0 and 3
months of treatment, are shown in Table 4.
Body weight
Body weight data were collected throughout the study, as both age, and dosing with paroxetine
can alter bodymass. In this study there were no differences in weight measures among experi-
mental groups, indicating no interference with the behavioural assessments.
Principal component analysis of OF, EPM, and SI variables
Four types of behaviour, i.e. principal components (PCs), which have biological relevance in
describing behaviour in the OF and EPM tests, were extracted by PCA. They were termed loco-
motion and anxiety-like behaviour, anxiety, exploration and risk assessment behaviour, and
stress-related vegetative behaviour. The definition of the individual behavioural types (PCs)
and the factor loadings obtained after Oblimin rotation are shown in Table 2. PCA on results
from the SI test extracted 4 principal components with eigenvalue higher than 1, which were
retained for Oblimin rotation. The four types of behaviour (PCs) were defined as aggression/
fighting, social activity, aggression, and memory for social interaction. The definition of the
individual behavioural types (PCs) and the factor loadings obtained after Oblimin rotation are
shown in Table 3.
Table 4. The serum paroxetine levels assessed by UHPLC-MS/MS.
Age (mth) Vehicle Paroxetine
Mean (nmol/l) Mice (n) Mean (nmol/l) SEM Mice (n)
9 n.d. 10 n.d. n.d. 10
12 n.d. 10 103 16 16
n.d. = not detected (values <20 nmol/l).
doi:10.1371/journal.pone.0165144.t004
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MANOVA on factorial scores obtained from the PCA. OverallMANOVA on factor
scores derived from PCA demonstrates differences related to locomotion and anxiety-like behav-
iour, F(15,197) = 7.803, p< 0.0001; exploration and risk assessment behaviour, F(15,197) = 3.154,
p = 0.00013; stress-related vegetative behaviour, F(15,197) = 11.024, p<0.0001; social activity (S2)
F(15,220) = 2.560, p = 0.002; and aggression, F(15,220) = 1.864, p = 0.029. There are no significant
differences in anxiety-like behaviour, F(15,197) = 1.689, p = 0.056; fighting/aggressivebehaviour,
F(15,220) = 1.594, p = 0.077, or memory for social interaction, F(15,220) = 1.329, p = 0.187. Factor
scores (Mean ± SEM) along with results from pairwise comparison are shown in Fig 1 (OF and
EPM tests) and Fig 2 (SI test).
Behavioural phenotype at 9 months of age
Behavioural testing at 9 months of age was performed prior to treatment start. As such, the 4
experimental groups at 9 months of age, depicted in Figs 1 and 2, are pseudo groups used for
monitoring the age-related changes in behaviour within the 4 experimental groups. To com-
pare the behavioural phenotypes of Wt and Tg animals at 9 months of age (S1–S3 Tables), we
used the average factor scores between the vehicle- and paroxetine-treated groups for Wt and
Tg animals, respectively. We detected no changes in behaviour in 9 month-old Tg animals
compared toWt animals.
Behavioural phenotype related to age, genotype and treatment
Age-related changes in behaviour analysedby PCA. Age-related changes in behaviour
observed in the OF and EPM tests were related to locomotion, exploration and risk assessment
behaviour, and stress-related vegetative behaviour with F(3,197) = 27.14 (p< 0.0001); 4.291
(p = 0.006) and 43.681 (p< 0.0001), respectively (S4 and S5 Tables). In the SI test age-related
changes were observedonly in social activity with F(3,220) = 6.643, p = 0.0002 (S6 Table).
WtVeh animals demonstrated an increase in stress-related vegetative behaviour from 15
months of age (Fig 1D), in fighting/aggression (S1) at 18 months of age (Fig 2A), in social activ-
ity from 12 months of age (Fig 2B), and in aggression at 12 and 18 months of age (Fig 2C).
TgVeh animals demonstrated reduced locomotion and anxiety-like behaviour during ageing
(Fig 1A) from 12 months of age, reduced exploratory and risk assessments behaviour (Fig 1C)
from 15 months of age, and increased stress-related vegetative behaviour from 15 months of
age (Fig 1D). WtPrx animals demonstrated reduced locomotion and anxiety-like behaviour
during ageing (Fig 1A) from 12 months of age, reduced exploratory and risk assessments
behaviour (Fig 1C) from 18 months of age, and increased stress-related vegetative behaviour
from 12 months of age (Fig 1D). TgPrx animals demonstrated reduced locomotion and anxi-
ety-like behaviour (Fig 1A), and increased stress-related vegetative behaviour (Fig 1D) during
ageing, both of which were evident from 15 months of age.
Changes in behaviour associated to the APP/PS1 genotype analysedby PCA. Changes
associated to the genotype were observed in stress-related vegetative behaviour F(1,197) =
12.168, p = 0.001, and aggression F(1,220) = 5.545 (p = 0.019).
Multivariate analysis of variances facilitated investigation of the interactions of different
parameters on the behaviour. We demonstrated an interaction between genotype and treat-
ment in locomotion and anxiety-like behaviour F(1,197) = 3.919, p = 0.049, exploration and
risk assessment behaviour F(1,197) = 15.216, p = 0.0001, and social activity F(1,220) = 4.851,
p = 0.029. Interaction between age, genotype and treatment was observed in locomotion and
anxiety-like behaviour F(3,197) = 3.039, p = 0.030, and in exploration and risk assessment
behaviour F(3,197) = 3.617, p = 0.014.
Phenotyping of an Alzheimer’s Disease Mouse Model following Paroxetine Treatment
PLOS ONE | DOI:10.1371/journal.pone.0165144 November 4, 2016 9 / 21
Fig 1. Effect of age, genotype and treatment on performance in OF (open field) and EPM (elevated plus maze) tests, analysed by principal
component analysis. Factor scores for 4 types of behaviour (principal components) are shown in A-D. MANOVA was used to analyse significance in
effect of age, genotype and treatment, followed by Fisher’s LSD post hoc test for group-wise comparisons: *, **, ***—p < 0.05, 0.01, 0.001
correspond to differences in factor scores between groups at 9, 12, 15 or 18 months of age; +, ++, +++—p < 0.05, 0.01, and 0.001 correspond to age-
effect within groups compared to factor scores at 9 months; ¤, ¤¤, ¤¤¤—p < 0.05, 0.01, 0.001 correspond to intra-group comparisons of factor scores
at 12 months. Bars indicate Means ± SEM Black bars, Wt (n = 14–15); white bars, Tg (n = 12–13); dark grey bars, Wt-paroxetine treated (n = 14–16);
light grey bars, Tg-paroxetine treated (n = 6–12, and n = 4 at 12 months of age). 9, 12, 15 and 18 months of age correspond to 0, 3, 6 and 9 months of
treatment, respectively.
doi:10.1371/journal.pone.0165144.g001
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Fig 2. Effect of age, genotype and treatment on social interaction, tested on two consecutive days, analysed by principal component
analysis. Factor scores for 4 types of behaviour (principal components) are shown in A-D. MANOVA was used to analyse significance in effect of age,
genotype and treatment, following by Fisher’s LSD post hoc test for group-wise comparisons: *, **, ***—p < 0.05, 0.01, 0.001 correspond to
differences in factor scores between groups at 9, 12, 15 or 18 months of age; +, ++, +++—p < 0.05, 0.01, and 0.001 correspond to age-effect within
groups compared to factor scores at 9 months; ¤, ¤¤, ¤¤¤—p < 0.05, 0.01, 0.001 correspond to intra-group comparisons of factor scores at 12 months.
Bars indicate Means ± SEM Black bars, Wt (n = 15–23); white bars, Tg (n = 12–22); dark grey bars, Wt-paroxetine treated (n = 14–16); light grey bars,
Tg-paroxetine treated (n = 7–12, and n = 3 at 12 months of age). 9, 12, 15 and 18 months of age correspond to 0, 3, 6 and 9 months of treatment,
respectively.
doi:10.1371/journal.pone.0165144.g002
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At 18 months of age TgVeh demonstrated reduced locomotor and anxiety-like behaviour
(Fig 1A), lower levels of exploratory behaviour (Fig 1C), and reduced social activity (Fig 2B)
compared toWtVeh. The reduced level of social activity in the TgVeh animals was significant
from 15 months of age. TgPrx animals show reduced locomotor activity from 15 months of age
compared toWtVeh.
MANOVA on the aggression/fighting variable demonstrated no differences (p = 0.077)
among groups, however, Fisher’s unprotected LSD test indicated reduced levels of aggression/
fighting (Fig 2A) at 18 months of age in both TgVeh and TgPrx animals compared toWtVeh.
At 15 months of age TgVeh animals showed higher levels of stress-related vegetative behav-
iour (Fig 1D) compared toWtVeh. However, at 18 months of age the differences did not per-
sist. We also observedhigher levels of stress-related vegetative behaviour in TgVeh animals at
9 months of age compared to Wt animals.
Behavioural changes associated to long-term treatment with paroxetine. Long-term
treatment with paroxetine was shown to have an effect on aggression (F(1,220) = 3.971,
p = 0.048). MANOVA demonstrated an effect of the interaction between genotype and treat-
ment on locomotion F(1,197) = 3.919, (p = 0.049), exploration and risk assessment behaviour
F(1,197) = 14.542, (p = 0.0001), and social activity, F(1,220) = 4.851 (p = 0.029). An interaction
between age and treatment F(3,197) = 3.248, (p = 0.023) was observed in locomotion and anxi-
ety-like behaviour, and the interaction between age, genotype and treatment was found in both
locomotion F(3,197) = 3.039, (p = 0.030), and exploration and risk assessment behaviour F
(3,197) = 3.617, (p = 0.014).
TgVeh versus TgPrx. Long-term treatment with paroxetine was found to affect behaviour
in the APP/PS1 mice.We observedhigher levels of explorative and risk assessment behaviour
from 15 months of age in TgPrx animals compared to TgVeh (Fig 1C). MANOVA revealed no
age-related changes in anxiety-like behaviour (Fig 1B). However, Fisher’s unprotected LSD test
indicated decreased levels of anxiety in TgPrx compared to WtVeh, significant from 15 months
of age. There were no differences in anxiety-levels betweenTgVeh and TgPrx animals. In Tg
animals social interaction (Fig 2) was not affected by long-term treatment with paroxetine.
Although, there were indications of social activity (Fig 2B) being affected by treatment, as the
reduced levels of social activity, observed in the TgVeh animals from 15 months of age com-
pared toWtVeh, were not replicated in TgPrx animals.
WtVeh versusWtPrx. Long-term treatment with paroxetine also affected behaviour in
theWt animals. WtPrx animals have reduced locomotion and anxiety-like behaviour from 15
months of age (Fig 1A), reduced exploration and risk assessment behaviour at 18 months of
age (Fig 1C), and reduced aggression/fightingbehaviour at 18 months of age (Fisher’s Unpro-
tected) (Fig 2A) compared toWtVeh.
Aß-plaque load
To assess whether treatment with paroxetine affects Aß plaque load in the APP/PS1 mice, and
whether Aß plaque load correlated to the behaviour observed in the OF test at 18 months of age,
we obtained preliminary data on Aß plaque load from 5 TgVeh and 5 TgPrxmice. The Aß pla-
que load provides an estimate of the percentage of the neocortex that is occupiedwith 6E10+
Aß-containing plaques. We observedno effect of long-term treatment with paroxetine on Aß
plaque load in neocortex of 18-month-old TgPrxmice (TgPrx: 15.9% ± 4.2% vs. TgVeh: 15.0% ±
3.0%, n = 5/group, p = 0.709), nor did we find any correlation betweenAß plaque load in the
neocortex and behaviour in the OF test (Total number of squares crossed) in neither untreated
(r = 0.016; p = 0.841), nor treated (r = 0.052; p = 0.713) mice.
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Discussion
Alzheimer’s disease is a neurodegenerative disorder associated with Aß deposition, synaptic
and neuronal loss [9, 28], and altered serotoninergic neurotransmission [29–31]. The APP/PS1
transgenic (Tg) mouse model was developed to mimic AD associated amyloid pathology in
humans based on mutations in APP (amyloid precursor protein) and PS1 (presenilin1) genes,
resulting in the formation of Aß plaques [32]. In the present study we have used a number of
behavioural tests to characterise behavioural abnormalities that can be attributed to either age-
ing and/or associated with formation of Aß plaques.
Possible role of serotonin in AD-like disease in mice
Liu et al. (12) have demonstrated 5-HT neuronal degeneration in APP/PS1 mice, associated
with lower levels of 5-HT and inversely to increasing Aß plaque load. Treatment with citalo-
pram has been shown to delay or interfere with the development of Aß plaques [15, 16]. The
use of another SSRI, paroxetine, in the 3xTgADmouse model, also exhibiting reduced 5-HT
levels [19], has likewise shown to delay or interfere with the development of Aß pathology and
to ameliorate behavioural deficits [18]. We examined whether long-term treatment with parox-
etine normalised behavioural changes observed in Tg mice by using paroxetine to increase
5-HT levels. Our results demonstrated that Tg mice develop a distinct phenotype, evident from
15 to 18 months of age. We also demonstrated that long-term treatment with paroxetine affects
behaviour in the Tg mice. Moreover, our study design allowed us to investigate the side effects
of paroxetine on behaviour inWt mice.
AD has been associated with non-cognitive neuropsychological symptoms related to
changes in 5-HT levels, such as activity disturbances, affective disturbances, aggression, stereo-
typic behaviour, and anxiety [11, 33]. Behavioural symptoms in the APP/PS1 mouse model,
which are correlated to neuropsychological clinical symptoms, include disturbances in locomo-
tor activity [34], anxiety [35, 36], aggression, and social behaviour [37–39]. The present study
thus focuses on performance in OF and EPM tests, in which animals are allowed to explore the
environment undisturbed, and where different behavioural parameters can be assessed, and on
the SI test, where interest to engage into social interaction is analysed. All three tests can be
used to evaluate the aforementioned behavioural symptoms.
Describing behavioural patterns using principal component analysis
Generalising our findings, 4 principal components (PCs) describing behaviour in the OF and
the EPM and 4 PCs describing social behaviour in the SI test were extracted by principal com-
ponent analyses (PCAs). The behaviour describedby the PC is directly associated with vari-
ables from the original data set that have a positive factor loading, and inversely associated
with variables, which have a negative factor loading. The PCs from the analysis on OF and
EPM variables were defined as locomotion and anxiety-like behaviour, anxiety, exploration
and risk assessment, and stress-related vegetative behaviour. Locomotion (PC D1) is directly
associated with variables related to motor activity (such as total squares crossed, and rearing
against walls, which for mice can be included as yet another measure of general locomotion,
and inversely associated with variables such as immobility time and stereotypy in OF, which is
interpreted as anxiety-related behaviour. A higher factor score on this variable indicates higher
levels of locomotor and anxiety-like activity. Anxiety-like behaviour (PC D2) is directly associ-
ated with variables having a high anxiolytic valence, and is inversely associated with time spent
in the closed arms of the EPM. A high factor score on this variable indicates reduced anxiety-
like behaviour. Exploration and risk assessment (PC D3) is describedby variables that are
related to explorative behaviour and Stretch-Attend-Postures, all observedwithin the closed
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arms of the EPM. Immobility time in EPM has a negative factor load on PC D3. A high factor
score on this variable indicates a high level of explorative and risk assessment behaviour.
Stress-related vegetative behaviour (PC D4) is directly associated with grooming actions and
inversely associated with the amount of urine traces. Some authors correlate grooming and uri-
nation with anxiety-like behaviour [40], but in our study these two behavioural variables regis-
tered in both OF and EPM tests were always describing a separate PC when performing
rotation analyses, indicating that they describe a type of behaviour, which is not directly corre-
lated to anxiety-related behaviour. We consider this type of behaviour as stress-related vegeta-
tive behaviour, and a high factor score on this variable indicates a high level of stress-related
vegetative behaviour.
Principal components from the analysis on social interaction variables (Table 3) differenti-
ate mainly according to the test day in question, thus number of aggressive incidents and time
spent in aggression on the second day define PC S1 (aggression/fighting).Latency to initial
contact on both days and social interaction on day 1 define PC S2 (social activity). The number
of aggressive incidents and the time spent in aggression on day 1 define PC S3 (aggression).
The total time of contact and the number of contacts on day 2 define PC S4 (memory for social
interaction). Both the S2 and the S4 behavioural variables might be a measure of anxiety-like
behaviour, since an increase in the time spent engaging in social contact is indicative of reduced
anxiety-like behaviour [41–43]. For all 4 PCs, a high factor score indicates more activity of the
specific type of behaviour in question.
No behavioural changes in 9 months old APP/PS1 mice compared to Wt
At 9 months of age there is no behavioural performance deficits in the Tg mice compared to
Wt littermate mice. Although a difference in stress-related vegetative behaviour betweenWt
and TgVeh animals at 9 months of age was observedwhen the mice were split into experimen-
tal groups, no differences were observedwhen the analysis comprised all Tg andWt mice. Any
biological variation in stress-related vegetative behaviour at 9 months of age in the Tg group is
overruled by age-related changes, seen as there are no differences among groups at 18 months
of age.
There are some reports indicating increased locomotion in the APP/PS1 mouse model [44],
and reduced anxiety-like behaviour at 7 months of age [35, 36]. Consistent with our findings,
however, there are also studies reporting no changes in OF activity in APP/PS1 mice at 7
months of age [36], at 10–15 months of age [45], and no changes in anxiety-related behaviour
at 10–15 months of age [45]. At 9 months of age 5-HT axonal degeneration is not yet evident,
and 5-HT levels are still unchanged according to Liu et al. [12]. Hence, any behavioural
changes in the APP/PS1 mouse model at this age are most likely not caused by changes in
5-HT levels.
Development of the APP/PS1 phenotype
Normal ageing progression as analysed in this study is characterised by an increase in stress-
related vegetative behaviour and increased social activity, and no changes in locomotion, anxi-
ety, exploration, aggression, and memory for social interaction. There are indications of an
age-related increase in aggression/fighting inWt animals, but the importance of this behaviour
might be overestimated, as the differences between groups are demonstrated without correc-
tion for multiple comparisons. These behavioural changes, demonstrated in theWt group, are
due to normal ageing processes and are unrelated to genotype and long-term treatment with
paroxetine.
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Ageing in Tg mice is associated with other parameters than inWt animals, and we demon-
strate reduced locomotion and anxiety-like behaviour, evident from 12 months of age, reduced
social activity at 15 months of age, and reduced explorative behaviour from 15 months of age.
Also, Tg animals do not demonstrate increased fighting behaviour at 18 months of age as
observed inWt animals.
It is well known, that AD patients exhibit changes in social behaviour [33], such as increased
aggressiveness, and reluctance to engage in social contact. Other murine models of AD also dis-
play increased aggressive behaviour [46, 47]. In the present study, changes in aggression levels
do not characterise the AD-like pathology, and are negligible compared toWt.
Our data demonstrate reduced social activity in Tg mice, which is in line with findings by
Filali et al. [39], who report that APPswe/PS1A246E mice are less willing to engage in social con-
tact and show reduced socialmemory. We find no changes in the memory for social interaction
(S4). We do report an increase in aggressive behaviour inWt mice on the first day of the SI test
compared to the second day. This is not reproduced in Tg mice, inferring that the ability to
recall social interaction is found inWt mice alone.
Most of the commonly used ADmouse models exhibit increased locomotor activity
(reviewed by Webster et al. [48]). However, no differences in overall activity or even hypoactiv-
ity has also been reported in APP/PS1 mice [49, 50]. Our study supports the findings of
reduced locomotion in APP/PS1 mice.
According to Liu et al. [12] anxiety, measured by increased thigmotaxis and reduced explo-
ration in the OF test, is not evident until 18 and 24 months of age, respectively. In line with
these findings, we see no differences in anxiety levels measured by the EPM test at 18 months
of age. However, Tg mice have reduced social activity in the SI test from 15 months of age,
which might be indicative of reduced anxiety-like behaviour. There are also reports indicating
that APP/PS1 mice exhibit decreased levels of anxiety, as assessed by EPM [35, 36, 49], while
others fail to replicate the anxiety-like phenotype [45, 51]. The test design of the EPM appara-
tuses might have contributed to the divergent findings. In the latter of the reported study, the
EPM apparatus used was 5 cm wide [51], the same as in the present study. This might have
introduced a high anxiogenic factor compared to the 10 cm wide apparatus used by Lalonde
et al. [36, 49], resulting in divergent results. The presence of anxiety-related behaviour in the
APP/PS1 mouse model is thus widely discussed [35, 36, 52] and our findings support the find-
ings of unchanged anxiety-levels, at least up to 18 months of age.
SSRI-dependent changes in behaviour
Long-term treatment with paroxetine affects the behavioural phenotype in the APP/PS1 mice
on some but not all behavioural parameters, suggesting that not all behavioural deficits in the
Tg mice can be ascribed to changes in/reduced 5-HT levels. Paroxetine-treatment does not
induce behavioural changes in either locomotor or anxiety-like activity, stress-related vegeta-
tive, aggressive or social behaviour in Tg animals. However explorative and risk assessment
behaviour is affected, and from 15 months of age after 6 months of paroxetine-treatment,
behaviour in Tg animals is reverted to a normalWt phenotype. Paroxetine-induced reduction
in anxiety-levels is implied from 15 months of age in Tg animals, however, at 18 months of age
the effect is decreased. The power of the statistical analysis might be improved by increasing
the number of observations, but an anxiolytic effect of paroxetine treatment is inferred at this
point. Neither Wt nor Tg mice exhibit changes in anxiety-related behaviour with age and par-
oxetine only affects this behaviour in Tg mice. Paroxetine-treatment also affects social behav-
iour in the Tg mice. Untreated Tg mice display reduced levels of social activity from 15 months
of age, which is not replicated in the paroxetine treated Tg animals.
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Effect of paroxetine on Aß plaque load
We observedno difference in neocorticalAß plaque load after 9 months treatment with parox-
etine. Although data are still preliminary this observation is potentially important since 4
months of treatment with Citalopram was shown to impede the development of Aß pathology
in 7-month-old APP/PS1 mice [15] and 5 months of treatment with paroxetine reduced Aß
pathology and ameliorated behavioural deficits in 10-month-old 3xTgADmice [18]. Our find-
ing of no difference in neocorticalAß plaque load may partly explain why we see only partial
effects of the long-term treatment with paroxetine on behaviour. We also investigated for cor-
relations betweenAß plaque load and behaviour in the OF test (Total number of squares
crossed), as we found the locomotor activity to be affected in Tg animals. There was no correla-
tion betweenAβ plaque load and ‘Total number of squares crossed’ in neither untreated or
treated mice. This indicates that the neocorticalAß plaque load per se is not responsible for the
changes in locomotor activity seen in the Tg mice.
Side effects of treatment with paroxetine
To control for side effects of paroxetine on behaviour, the WtPrx group was included in the
study, and the results demonstrate that long-term treatment with paroxetine has distinct effects
onWt and Tg animals. In Wt mice the negative side effects of treatment are pronounced, and
the paroxetine-treatedWt mice display a behavioural phenotype similar to untreated Tg mice,
characterised by a decline in both motor activity, and explorative and risk assessment behav-
iour as well as in social behaviour. This differential effect on behaviour inWt and Tg mice
emphasises the importance of applying a diseasemodel when examining the effect and mecha-
nisms of drug action.
Longitudinal study
Most behavioural studies performed on the APP/PS1 mouse model have assessed behaviour at
a certain age, providing a snapshot of the behavioural phenotype. Longitudinal studies are few,
and the evaluation of results from studies at different ages, and with different methodologies is
difficult.We believe that for a detailed description of the behavioural changes, longitudinal
studies are needed to assess the age-related progression of the APP/PS1 phenotype. Our results,
based on a large number of animals, indicate that the APP/PS1 non-cognitive behavioural phe-
notype is only beginning to emerge from 15 months of age.
We took advantage of PCA to provide general conclusions on the behavioural phenotype of
APP/PS1 mice. PCA allowed us to mathematically combine different variables to pinpoint
major behavioural patterns. This procedure is an important part of the study and the impor-
tance of the general conclusions derived from the results of the PCA is highly valuable, as the
conclusions are based on the combined results obtained from the data sets of the whole study.
Conclusion
The APP/PS1 mouse model is appropriate for investigating the progression of an AD-like
pathology. The PCA is a helpful tool in distinguishing specific types of behaviour and to gener-
alise results derived from a big data set.
We find that APP/PS1 mice exhibit a specific age-related behavioural phenotype that mani-
fests itself from about 15 months of age when 5-HT levels are reduced [21].
Long-term effect of chronic treatment with the SSRI, paroxetine, in APP/PS1 mice is signifi-
cant regarding behaviour related to anxiety, exploration and risk assessment, and activity. This
indicates that the analysed behavioural changes are related to changes in serotonin levels. Our
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results indicate that the effect of paroxetine can be evaluated by locomotion, exploration and
risk assessment as well as anxiety-related behaviour. The evaluation of changes in social behav-
iour is relevant only in aged APP/PS1 mice. Longitudinal studies are necessary to describe the
development of a behavioural phenotype resembling the neuropsychiatric symptoms seen in
AD, as well as the effect of treatment with SSRI.
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